It seems unlikely that American poet and civil rights activist Maya Angelou spent much time thinking about translational research. But two quotes of hers capture the essence of the interplay between bench and bedside: “I did then what I knew how to do. Now that I know better, I do better” and “I’ve learned that I still have a lot to learn.” At the 2023 Annual Congress of the European Academy of Neurology, Mary Reilly described the relationship between bench and bedside as “a continuous circle of translation,” with each cycle beginning with patients and their needs. Read More

Traumatic brain injury (TBI) is an alteration in brain function that occurs when a sudden external force traumatically impacts the brain and is frequent in vehicle accidents or sports injuries. There is no treatment for TBI to date, but recent research has opened a new avenue coming from the neuroprotective role of the liver. Read More

Researchers from University North Carolina, Chapel Hill have discovered prostate-specific member antigen (PSMA)-targeted agents with reduced salivary gland uptake while maintaining high tumor uptake. Synthesis and subsequent screening of PSMA agents bearing different chelators and targeting ligands led to the identification of two lead agents, NOTA-UNC-PSMA-2 and DOTA-UNC-PSMA-2. Read More

Researchers from China Pharmaceutical University have reported the discovery of novel orally bioavailable fms-like tyrosine kinase 3 (FLT3) inhibitors as potential candidates for the treatment of acute myeloid leukemia (AML). Synthesis and optimization of a novel series of FLT3 inhibitors led to the identification of LT-540-717 as the lead candidate. Read More

A Cytosite Biopharma Inc. patent describes prodrugs of granzyme B-targeting compounds reported to be useful as granzyme B-imaging agents for the diagnosis of cancer. Read More

Interleukin-17 (IL-17), a cytokine produced by T helper 17 (Th17) cells, is a key player in host inflammation and immune dysfunction leading to autoimmune diseases such as psoriasis, rheumatoid arthritis, multiple sclerosis or asthma, among others. Read More

Menin (MEN1)/MLL interaction inhibitors are reported in a Bala Therapeutics Inc. patent as potentially useful for the treatment of cancer and diabetes. Read More

Novel therapeutic strategies are urgently needed to treat glioblastoma, the most aggressive type of primary brain tumor frequently associated with poor survival. Read More

Given the high prevalence of chronic kidney disease and the impact of renal fibrosis on the prognosis of these patients, there is a need for novel diagnostic tools to be able to detect pathological changes earlier and thus avoid progression to later stages of the disease. Read More

Chengdu Brilliant Pharmaceutical Co. Ltd. and ScinnoHub Pharmaceutical Co. Ltd. have jointly reported macrocyclic dual specificity protein kinase CLK2 and/or dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors. Read More

The c-Myc oncogene is overexpressed in a significant proportion of human cancers, including difficult-to-treat triple-negative breast cancers (TNBC). In the pursuit of novel anti-TNBC agents, there is a growing interest in ligands that can stabilize c-Myc promoter G-quadruplex (G4), thereby inhibiting c-Myc expression. Read More

Despite the success of CAR T-cell therapies for cancer immunotherapy, only a small percent of patients have a significant clinical response, and it is difficult to distinguish responders from nonresponders at an early stage with current imaging techniques. Read More